Teduglutide: A Literature Course on What the Studies Report

This page is a reading course, not a protocol. It walks through the published teduglutide literature in six modules: what the compound is, how its mechanism has been described, what outcomes individual studies reported, what adverse events appear in print, what pharmacokinetic information exists, and how the compound is regulated. Each module closes with the limits of the evidence it rests on. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision.

Module 1: What Teduglutide Is and How It Has Been Studied

Definition and class

Teduglutide has been described in the clinical nutrition literature as an analogue of glucagon-like peptide-2 (GLP-2) — an enteroendocrine hormone — developed for patients with short bowel syndrome who depend on parenteral support, and a 2023 review set out its indications and reported results in that population (PMID 37421385). It belongs to the gut peptide hormone analogue class rather than to the incretin (GLP-1) class, although both peptides derive from proglucagon processing, a framing used in the same review of short bowel indications (PMID 37421385).

Origin and forms

Teduglutide is a recombinant peptide manufactured for subcutaneous administration and is supplied as an approved prescription medicine in short bowel syndrome, the setting in which the reviewed clinical experience was accumulated (PMID 37421385). Separately, research-grade vials labelled "for research use only" circulate outside the pharmaceutical supply chain; no study in this course used such material, and none of the verified papers evaluated non-pharmaceutical preparations.

How it has been studied

The verified literature reviewed here spans several study designs. Registration-era randomised evidence is summarised second-hand inside review articles, while the primary reports available in this set are observational: single-centre long-term cohorts, national real-life paediatric series, multicentre surveys in transplant medicine, individual case reports, and one rodent experiment.

Limits of Module 1 evidence

This module describes categories, not effects. The verified set is weighted toward small observational reports and reviews; it contains no head-to-head comparison with another gut peptide, no long-duration randomised trial published as a primary paper here, and no study of research-grade material. Class descriptions drawn from reviews are summaries of other people's data and inherit their uncertainties.

Module 2: Mechanism as Described in the Literature

The mechanistic rationale repeated across the short bowel literature is intestinal adaptation: a GLP-2 analogue is used with the aim of supporting the absorptive capacity of remaining bowel in patients dependent on parenteral nutrition, and a 2023 review organised the reported clinical results around that adaptation rationale (PMID 37421385). Native GLP-2 is rapidly degraded by dipeptidyl peptidase-4, and the analogue was designed to resist that degradation so that receptor exposure is prolonged relative to the native hormone — the design premise underlying the clinical programme summarised in that review (PMID 37421385).

Two lines of work in the verified set probe mechanism more directly. Researchers gave teduglutide perioperatively to rats and measured intestinal inflammatory and redox responses, treating oxidative-stress and inflammation markers in bowel tissue as the mechanistic readout (PMID 28902941). In children with short bowel syndrome, the study of citrulline levels and the anatomical location of remnant small intestine used plasma citrulline as a surrogate for functional enterocyte mass and examined whether remnant anatomy tracked with response (PMID 40868429).

A third mechanistic framing appears in transplant medicine. Reports of teduglutide in treatment-refractory severe intestinal acute graft-versus-host disease described its use where the rationale is repair of a damaged intestinal epithelium rather than adaptation after resection (PMID 40229535), and a paediatric and young-adult series applied the same reasoning to gastrointestinal graft-versus-host disease (PMID 38311212).

Limits of Module 2 evidence

Mechanism here is inferred, not demonstrated in humans. The rodent experiment measured tissue markers in rats, not clinical outcomes in people (PMID 28902941). Citrulline is a surrogate, and an association between a surrogate and response does not establish the causal pathway (PMID 40868429). Mucosal-repair reasoning in graft-versus-host disease was drawn from uncontrolled clinical experience.

Module 3: Reported Outcomes by Study

Adults with short bowel syndrome

The 2023 review of indications and results in short bowel patients reported that reduction of parenteral support requirements — with weaning from parenteral support in a subset of treated patients — was the outcome most consistently described across the available clinical experience (PMID 37421385). A single-centre report of long-term outcomes followed treated patients beyond the horizon of registration studies and described the trajectory of parenteral support and treatment continuation over extended follow-up (PMID 32391948). A further clinical report asked explicitly whether treated short bowel syndrome patients returned toward normal daily life, placing patient-level function alongside nutritional endpoints (PMID 34614239). A Spanish-language discussion article posed the question of what happens after teduglutide, addressing the clinical situation of patients once treatment is interrupted or has run its course (PMID 32406744).

Children with short bowel syndrome

A real-life single-country paediatric experience reported that response to teduglutide was variable between children rather than uniform, and the authors framed variability itself as the principal finding (PMID 35730756). A 2025 paediatric analysis examined efficacy in relation to citrulline levels and to the anatomical location of the remnant small intestine, testing whether baseline biology and anatomy corresponded with the observed response (PMID 40868429). Growth was studied separately: researchers described the growth trajectories of children with short bowel syndrome across the first year of teduglutide treatment, using anthropometric change over time as the endpoint (PMID 42275987).

Off-label and case-level use

Beyond short bowel syndrome, an off-label report described teduglutide use in patients with chronic malabsorption who did not have intestinal failure, extending observation to a population outside the approved indication (PMID 30730014). A 2023 case report described teduglutide in amyloidosis-associated intestinal failure, a single-patient observation rather than a comparative result (PMID 37601424). In transplant medicine, a multicentre survey collected experience with teduglutide in treatment-refractory severe intestinal acute graft-versus-host disease (PMID 40229535), and a 2024 series reported its use in the management of gastrointestinal graft-versus-host disease in children and young adults (PMID 38311212).

Animal work

The rodent study administered teduglutide perioperatively and reported intestinal inflammatory and redox responses in rat bowel tissue, an endpoint set that cannot be mapped onto patient-level nutritional outcomes (PMID 28902941).

Limits of Module 3 evidence

Most of these reports were uncontrolled. Single-centre cohorts, national real-life series, surveys and case reports are open to selection effects, and parenteral support volume is a management decision as much as a physiological measurement. The paediatric literature itself emphasised heterogeneity of response (PMID 35730756), and graft-versus-host disease experience was gathered in patients receiving multiple concurrent therapies (PMID 40229535). None of these papers supports a general promise of benefit for any individual.

Module 4: Teduglutide Side Effects: What Studies Report

Safety in this literature is reported alongside efficacy rather than in dedicated safety trials. The 2023 review of indications and results in short bowel syndrome addressed tolerability and the practical monitoring that accompanies treatment as part of its account of clinical use (PMID 37421385). The single-centre long-term outcomes report is informative for the same reason: by following patients over extended periods, researchers described treatment continuation, interruption and discontinuation as they occurred in routine care (PMID 32391948).

Gastrointestinal complaints and stoma-related changes are the adverse-event categories most often described in the short bowel syndrome experience summarised by that review (PMID 37421385), and long-term follow-up reporting from a single centre described adverse events and complications arising during continued treatment (PMID 32391948). Off-label use outside intestinal failure was also reported with tolerability observations, since the authors extended treatment to patients with chronic malabsorption who differed from the licensed population (PMID 30730014).

In transplant medicine, adverse events are difficult to attribute. The multicentre survey in treatment-refractory severe intestinal acute graft-versus-host disease described outcomes in critically ill patients receiving immunosuppression and supportive care simultaneously, so events recorded during treatment cannot be assigned to teduglutide alone (PMID 40229535). The paediatric and young-adult gastrointestinal graft-versus-host disease series faced the same attribution problem in a younger population (PMID 38311212). A single case report in amyloidosis-associated intestinal failure describes one patient's course only and carries no adverse-event rate (PMID 37601424).

Limits of Module 4 evidence

No paper in the verified set was designed primarily as a safety study, and none provides pooled incidence figures that could be quoted as a rate. Observational reports capture events that clinicians chose to record. Approved product labelling, not this page, is the reference document for a full adverse-event profile, contraindications and monitoring requirements, and that labelling is interpreted by a prescriber.

Module 5: Pharmacokinetics Where Data Exist

The verified papers in this course were not pharmacokinetic studies, and none reported absorption, distribution, half-life or clearance values. What they provide instead is the design rationale and pharmacodynamic surrogates. The review of short bowel indications explained that teduglutide was engineered to resist dipeptidyl peptidase-4 degradation so that exposure is extended compared with native GLP-2, which is the pharmacokinetic premise of the compound's clinical use (PMID 37421385).

On the pharmacodynamic side, plasma citrulline was used in a paediatric analysis as a measurable correlate of intestinal absorptive mass in relation to treatment response (PMID 40868429), and growth measurements over the first treatment year served as a downstream physiological marker in children (PMID 42275987). Long-term clinical follow-up from a single centre provides the closest thing to durability information in this set, describing what happened across extended treatment rather than measuring drug concentrations (PMID 32391948).

Limits of Module 5 evidence

Because no verified paper measured plasma teduglutide, this course states no half-life, no bioavailability figure and no dosing interval. Surrogate markers such as citrulline describe biology, not drug exposure, and paediatric physiology cannot be assumed to mirror adult kinetics.

Module 6: Regulatory Status

Teduglutide is an approved prescription medicine for short bowel syndrome in patients dependent on parenteral support in major regulatory jurisdictions, and the clinical review of indications and results describes its use within that approved framework (PMID 37421385). Approved use requires a prescription, and administration in the published cohorts occurred under specialist intestinal failure or paediatric gastroenterology care (PMID 32391948).

Several uses in this literature sit outside approved indications. The chronic malabsorption report was explicitly labelled off-label therapy in patients without intestinal failure (PMID 30730014), and the graft-versus-host disease experience was collected as survey and series data in a setting where teduglutide is not an approved treatment (PMID 40229535). Off-label prescribing is a decision made by licensed clinicians within their own regulatory environment.

Two further categories are worth stating plainly. Peptide material sold as "research use only" is intended for laboratory work and is not an approved medicine, is not manufactured to pharmaceutical standards for human administration, and was not the material used in any study cited here. Separately, pharmacy compounding of copies of approved drug products is constrained in the United States by federal rules on essentially copying commercially available approved products, and rules differ by jurisdiction and over time. Regulatory status changes; none of this is legal advice.

Limits of Module 6 evidence

Approval status and compounding rules are jurisdiction-specific and are not established by the papers cited above, which describe clinical practice rather than law. Approval for one indication says nothing about evidence in another, and the off-label reports in this set were small and uncontrolled (PMID 30730014).

What the Studies Did Not Test

The verified literature did not test teduglutide in healthy adults, in athletic or body-composition contexts, or for general "gut health" in people without intestinal disease; the populations studied were patients with short bowel syndrome, chronic malabsorption, amyloidosis-associated intestinal failure and gastrointestinal graft-versus-host disease (PMID 37421385, PMID 38311212). It did not compare teduglutide with other GLP-2 analogues or with GLP-1 receptor agonists in any head-to-head design within this set. It did not characterise pharmacokinetics, and it did not establish incidence rates for individual adverse events. The paediatric work reported variability of response rather than a predictable outcome (PMID 35730756), and questions about the period after treatment ends were raised as open clinical questions rather than answered (PMID 32406744). This page describes what researchers reported; it is educational only and is not medical advice.

References

• The indications and results of the use of teduglutide in patients with short bowel (Current Opinion in Clinical Nutrition and Metabolic Care, 2023)
• Long-Term Outcomes With Teduglutide From a Single Center (JPEN, 2021)
• Teduglutide in short bowel syndrome patients: A way back to normal life? (JPEN, 2022)
• [Is there life after teduglutide?] (Nutricion Hospitalaria, 2020)
• The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience (Journal of Pediatric Gastroenterology and Nutrition, 2022)
• Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine (Children, 2025)
• Growth trajectories of children with short bowel syndrome during the first year of teduglutide treatment (Clinical Nutrition, 2026)
• Off-Label Teduglutide Therapy in Non-intestinal Failure Patients with Chronic Malabsorption (Digestive Diseases and Sciences, 2019)
• Teduglutide in amyloidosis-associated intestinal failure (Clinical Case Reports, 2023)
• Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey (Bone Marrow Transplantation, 2025)
• Use of Teduglutide in the Management of Gastrointestinal Graft-versus-Host Disease in Children and Young Adults (Transplantation and Cellular Therapy, 2024)
• Intestinal inflammatory and redox responses to the perioperative administration of teduglutide in rats (Acta Cirurgica Brasileira, 2017)